The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2023 Jun 23

PMID 37351685

Authors

Mary Henderson

Heather-Marie A Schmidt

Lastone Chitembo

Hortencia Peralta

Ahmed S Alaama

Cheryl Johnson

Rachel Baggaley

Robin Schaefer

Affiliations

Soon will be listed here.

Abstract

Differentiated service delivery and new products, such as long-acting injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre-exposure prophylaxis (PrEP) for HIV prevention. We explored PrEP provider perspectives on differentiated PrEP service delivery and new PrEP products to inform World Health Organization (WHO) guidelines and programme implementation. 150 PrEP providers who participated in a WHO survey were randomly selected and 67 were invited for interviews based on geographic representation, provider cadre, gender, experience with community-based PrEP service delivery, and familiarity with new PrEP products. Semi-structured interviews were conducted virtually. Key themes were inductively extracted relating to differentiated service delivery and benefits and concerns regarding new PrEP products. 30 PrEP providers from 24 countries were interviewed. Across regions, providers were supportive of differentiated service delivery to respond to clients' needs and preferences, maintain services during COVID-19, and ensure access for priority populations that may face access challenges. Providers welcomed prospects of offering CAB-LA to their clients but had concerns about HIV testing, costs, and the need for clinic-based services, including staff who can administer injections. Providers felt the DVR was potentially important for some cisgender women, especially young clients and female sex workers, and raised fewer concerns compared to injectable PrEP. Providers' views are critical for the development of guidelines and implementing programmes that will best serve PrEP users. Understanding areas where provider capacities and biases may create barriers can define opportunities for training and support to ensure that providers can deliver effective programmes.

Citing Articles

Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort.

Cooney E, Reisner S, Poteat T, Radix A, Mayer K, Beyrer C AJPM Focus. 2025; 4(2):100313.

PMID: 40051448 PMC: 11880704. DOI: 10.1016/j.focus.2025.100313.

Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP.

Glick J, Nestadt D, Sanchez T, Li K, Hannah M, Rawlings M J Int Assoc Provid AIDS Care. 2024; 23:23259582241293336.

PMID: 39698980 PMC: 11788811. DOI: 10.1177/23259582241293336.

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods.

Bishopp C, Mungai-Barris Z, Briedenhann E, Donaldson E, Irungu E, Schwartz K Curr HIV/AIDS Rep. 2024; 22(1):7.

PMID: 39644439 PMC: 11625055. DOI: 10.1007/s11904-024-00715-y.

Leveraging international stakeholders' experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study.

Heck C, Kripke K, Dam A, Torres-Rueda S, Bozzani F, Obermeyer C Health Res Policy Syst. 2024; 22(1):156.

PMID: 39587579 PMC: 11587620. DOI: 10.1186/s12961-024-01240-5.

Acceptability of six-monthly PrEP dispensing supported with interim HIV self-testing to simplify PrEP delivery in Kenya: findings from qualitative research.

Thuo N, Bardon A, Mogere P, Kiptinness C, Casmir E, Wairimu N BMC Health Serv Res. 2024; 24(1):1281.

PMID: 39448999 PMC: 11515400. DOI: 10.1186/s12913-024-11521-y.

References

Ahluwalia A, Inzaule S, Baggaley R, Vitoria M, Schaefer R, Schmidt H . Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis. AIDS. 2022; 36(13):1897-1898. PMC: 9594132. DOI: 10.1097/QAD.0000000000003322. View

Schaefer R, Schmidt H, Ravasi G, Mozalevskis A, Rewari B, Lule F . Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021; 8(8):e502-e510. PMC: 8332196. DOI: 10.1016/S2352-3018(21)00127-2. View

Calabrese S, Tekeste M, Mayer K, Magnus M, Krakower D, Kershaw T . Considering Stigma in the Provision of HIV Pre-Exposure Prophylaxis: Reflections from Current Prescribers. AIDS Patient Care STDS. 2019; 33(2):79-88. PMC: 6386080. DOI: 10.1089/apc.2018.0166. View

Pleuhs B, Quinn K, Walsh J, Petroll A, John S . Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review. AIDS Patient Care STDS. 2020; 34(3):111-123. PMC: 7087402. DOI: 10.1089/apc.2019.0189. View

Wisutep P, Sirijatuphat R, Navanukroh O, Phatharodom P, Werarak P, Rattanasuwan W . Attitudes towards, knowledge about, and confidence to prescribe antiretroviral pre-exposure prophylaxis among healthcare providers in Thailand. Medicine (Baltimore). 2021; 100(49):e28120. PMC: 8663816. DOI: 10.1097/MD.0000000000028120. View

Matambanadzo P, Busza J, Mafaune H, Chinyanganya L, Machingura F, Ncube G . "It went through the roof": an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid-19. J Int AIDS Soc. 2021; 24 Suppl 6:e25813. PMC: 8554216. DOI: 10.1002/jia2.25813. View

Rosen J, Zhang L, Pelaez D, Coleman J, To C, Cooper L . Provider Perspectives on HIV Pre-Exposure Prophylaxis Service Disruptions and Adaptations During the COVID-19 Pandemic in Baltimore, Maryland: A Qualitative Study. AIDS Patient Care STDS. 2022; 36(8):313-320. PMC: 9419971. DOI: 10.1089/apc.2022.0058. View

Calabrese S, Magnus M, Mayer K, Krakower D, Eldahan A, Gaston Hawkins L . "Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation. AIDS Patient Care STDS. 2017; 31(4):196-204. PMC: 5404273. DOI: 10.1089/apc.2017.0002. View

Wulandari L, He S, Fairley C, Bavinton B, Marie-Schmidt H, Wiseman V . Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. EClinicalMedicine. 2022; 51:101507. PMC: 9284393. DOI: 10.1016/j.eclinm.2022.101507. View

10.

Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, Vijver D . Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023; 10(4):e254-e265. PMC: 10065903. DOI: 10.1016/S2352-3018(22)00365-4. View

11.

Hull S, Tessema H, Thuku J, Scott R . Providers PrEP: Identifying Primary Health care Providers' Biases as Barriers to Provision of Equitable PrEP Services. J Acquir Immune Defic Syndr. 2021; 88(2):165-172. PMC: 8577287. DOI: 10.1097/QAI.0000000000002750. View

12.

Mugwanya K, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel E . Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya. PLoS Med. 2019; 16(9):e1002885. PMC: 6719826. DOI: 10.1371/journal.pmed.1002885. View

13.

Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L . Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021; 385(7):595-608. PMC: 8448593. DOI: 10.1056/NEJMoa2101016. View

14.

Murphy E, Doherty M, El Sadr W, Zaidi I, Kamarazulman A, Crowley S . Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19. Lancet HIV. 2022; 9(12):e884-e886. PMC: 9616538. DOI: 10.1016/S2352-3018(22)00268-5. View

15.

Schmidt H, Schaefer R, Nguyen V, Radebe M, Sued O, Rodolph M . Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?. Lancet HIV. 2022; 9(5):e363-e366. PMC: 9046094. DOI: 10.1016/S2352-3018(22)00006-6. View

16.

Schmidt H, Rodolph M, Schaefer R, Baggaley R, Doherty M . Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice. J Int AIDS Soc. 2022; 25(7):e25963. PMC: 9334859. DOI: 10.1002/jia2.25963. View

17.

Kerzner M, DE A, Yee R, Keating R, Djomand G, Stash S . Pre-exposure prophylaxis (PrEP) uptake and service delivery adaptations during the first wave of the COVID-19 pandemic in 21 PEPFAR-funded countries. PLoS One. 2022; 17(4):e0266280. PMC: 8982838. DOI: 10.1371/journal.pone.0266280. View

18.

Brown E, Hendrix C, van der Straten A, Kiweewa F, Mgodi N, Palanee-Philips T . Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020; 23(11):e25634. PMC: 7673220. DOI: 10.1002/jia2.25634. View

19.

Eshleman S, Fogel J, Halvas E, Piwowar-Manning E, Marzinke M, Kofron R . HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. J Infect Dis. 2022; 226(12):2170-2180. PMC: 10205624. DOI: 10.1093/infdis/jiac415. View

20.

Krakower D, Mayer K . Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS. 2012; 7(6):593-9. PMC: 3769645. DOI: 10.1097/COH.0b013e3283590446. View